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Background:  The presence of pulmonary hypertension (PH) increases mortality in patients with left heart disease but the true prevalence 
is unknown. The purpose of this study was to determine the prevalence of PH in the setting of left heart disease (PH-LHD) in patients 
undergoing a clinical right heart catheterization (RHC) at our institution.
methods:  Hemodynamic data was obtained from all patients undergoing a RHC at the University of Pittsburgh Medical Center between 
2005 and 2012. Patients where hemodynamically stratified based on their first catheterization as having no PH (mPAP < 25 mmHg), 
pulmonary arterial hypertension (PAH; mPAP ≥ 25 mmHg and PCWP < 15 mmHg) or PH-LHD (mPAP ≥ 25 mmHg and PCWP ≥ 15 mmHg).
results:  At the time of the first RHC, 44% of the patients could be classified as having PH due to left heart disease (PH-LHD) (Table). 
Patients with PH-LHD have a mixed hemodynamic phenotype of pulmonary hypertension with increased right atrial and mean PA pressure 
and reduced stroke volume, compliance and cardiac index. Their transpulmonary gradient (TPG) is between the levels of those with no PH 
and those with PAH. The diastolic pulmonary gradient (DPG) is only elevated in the PAH group.
conclusion:  PH in the setting of left heart disease is very prevalent in patients undergoing a RHC. Their hemodynamics suggest a 
moderate form of PH but further investigation is required to determine the degree of pulmonary vascular disease in these patients and who 
is most likely to benefit from therapy.
Table 1. 
RHC hemodynamics. Values are mean ± SD. *P < 0.05 vs No PH, †P < 0.05 vs PAH
No PH
mPAP < 25 mmHg
PAH
mPAP ≥ 25 mmHg;
PCWP < 15 mmHg
PH-LHD
mPAP ≥ 25 mmHg;
PCWP ≥ 15 mmHg
n = 4387 n = 1849 n = 4795
Age (years) 60 ± 14 61 ± 14 63 ± 29*†
BMI 28.0 ± 6.7 29.1 ± 7.5* 30.7 ± 8.2*†
BSA (m2) 1.93 ± 0.29 1.92 ± 0.27 2.00 ± 0.28*†
RAP (mmHg) 5 ± 4 8 ± 5* 14 ± 7*†
mPAP (mmHg) 19 ± 4 34 ± 11* 38 ± 10*†
PCWP (mmHg) 10 ± 4 11 ± 3* 25 ± 14*†
CI (L/min/m2) 3.0 ± 0.9 2.9 ± 0.8 2.7 ± 0.9*†
TPG (mmHg) 9 ± 3 23 ± 12* 14 ± 15*†
DPG (mmHg) 0 ± 4 8 ± 10* -1 ± 14†
PVR (mmHg/L/min) 1.7 ± 0.9 4.7 ± 3.5* 2.9 ± 3.9*†
SV (ml) 80 ± 38 74 ± 29* 74 ± 39*
Ca (ml/mmHg) 4.3 ± 2.3 2.5 ± 1.9* 2.4 ± 1.5*
